Esophageal dysmotility in patients undergoing photodynamic therapy

OBJECTIVE: To study the esophageal motility of patients with esophageal adenocarcinoma or Barrett esophagus with high-grade dysplasia before and after photodynamic therapy. PATIENTS AND METHODS: In this prospective study conducted between January 1998 and October 1999, esophageal motility testing of the lower esophageal sphincter and esophageal body was performed with a water-perfused catheter, 2 days before and at least 3 weeks after patients underwent photodynamic therapy for esophageal adenocarcinoma or Barrett esophagus. Results were classified as normal motility, ineffective esophageal motility, or aperistalsis. RESULTS: Twenty-three patients were studied, 13 with carcinoma and 10 with Barrett esophagus. Overall, 11 patients (48%) had normal motility, 6 (26%) had ineffective esophageal motility, and 6 (26%) had aperistalsis. Five patients with aperistalsis had carcinoma. Follow-up tracings after photodynamic therapy found that 6 patients (26%) had normal motility, 7 (30%) had ineffective esophageal motility, and 10 (43%) had aperistalsis. CONCLUSIONS: Esophageal dysmotility is common in patients with esophageal adenocarcinoma or Barrett esophagus. Photodynamic therapy may worsen esophageal motility in some patients. Dysphagia after photodynamic therapy therefore may be related to underlying esophageal dysmotility and may not always be caused by stricture or underlying carcinoma.     

Radiographic abnormalities in eosinophilic esophagitis

Eosinophilic gastroenteritis is an unusual condition of unknown cause in which there is eosinophilic infiltration of the gastrointestinal tract usually accompanied by a peripheral eosinophilia. Rarely, it can also involve the esophagus. Recently, the authors have encountered 3 cases of eosinophilic infiltration of the esophagus. All patients had a strong history of allergies. Two of our patients have had upper esophageal strictures, as have 2 other previously reported cases. This appears to be the most common manifestation. One patient had polypoid lesions of the esophagus as well as of the rest of the gastrointestinal tract. Motility disturbances may also be present. Although steroid treatment may be beneficial, the esophageal strictures usually require mechanical dilatation to relieve submucosal fibrosis. This entity should be considered in any patient who has an esophageal disorder in the presence of either a strong history of allergy or peripheral eosinophilia.     

Otorhinolaryngologic manifestations of eosinophilic esophagitis

Similar to gastrointestinal symptoms of eosinophilic esophagitis (EE), symptoms of otorhinolaryngologic disease associated with EE often are refractory to traditional treatment of gastroesophageal reflux disease. Patient demographics and characteristics often are similar. Clinicians must maintain a high index of suspicion to accurately diagnose and manage airway findings related to esophagitis. Team collaboration between otolaryngologists, allergists, and gastroenterologists will assure the best treatment in this select group of predisposed patients.     

Noninvasive markers of eosinophilic esophagitis

There has been an increasing awareness and recognition of eosinophilic esophagitis (EE), a chronic condition with periods of exacerbation and remission, over the last decade. The complex pathophysiology of EE and eosinophil physiology provide several candidate biomarkers that could be studied on various noninvasively obtained body specimens. This article reviews several potential noninvasive biomarkers of EE.     

Nutritional management of eosinophilic esophagitis

Eosinophilic esophagitis has been increasingly described in pediatric and adult literature. Several pediatric studies have indicated that food allergies are responsible for more than 90% of pediatric cases. There are three different dietary approaches to the management of eosinophilic esophagitis: (1) the elemental diet, (2) the removal of foods based on allergy testing, and (3) the removal of the foods that most commonly cause eosinophilic esophagitis. This article discusses the nutritional risks and benefits of each approach.     

Histopathologic features of eosinophilic esophagitis

The pathology of eosinophilic esophagitis (EE) when fully developed in humans is highly characteristic and readily discriminated from the histology of the normal esophagus. The histologic alterations are not pathognomonic for any of the multiple causes of EE, and the correct diagnosis can be made only if the histology is correlated with clinical findings. The histology of the normal esophagus is reviewed and contrasted with the findings in EE. The characteristic findings in EE are illustrated. Selected research in humans and animal models pertinent to EE are briefly reviewed.     

Pharmacologic treatment of eosinophilic esophagitis

There are several treatment options available for patients who have eosinophilic esophagitis (EE). These options include dilatation for mechanical esophageal abnormalities, pharmacologic therapy, and dietary management. Providing the appropriate therapy depends on the significance of clinical symptoms, association of abnormal anatomy, and histologic involvement of underlying the esophageal tissue. This article focuses on the pharmacotherapy of EE.     

Basic pathogenesis of eosinophilic esophagitis

Eosinophilic esophagitis (EE) is a newly recognized disease, which has largely been called idiopathic EE, emphasizing the poor understanding of its pathogenesis. EE is a severe disease of the esophagus characterized by an accumulation of eosinophils in the esophageal mucosa, and is highly associated with atopic disease. Nevertheless, the nomenclature "eosinophilic esophagitis" describes only the tip of the iceberg of a complex disorder, as the pathogenesis of EE involves multiple tissues, cell types, and genes, and derives from complex genetic and environmental factors. This article defines the fundamental knowledge available to date that characterizes the mechanisms by which certain etiological factors cause EE, reviewing human studies, murine models, and recent knowledge regarding the involvement of environmental, cellular, molecular, and genetic factors in the development of EE.     

Epidemiology and etiology of eosinophilic esophagitis

Eosinophilic esophagitis (EE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal mucosa. Symptoms of EE are variable, and include gastroesophageal reflux symptoms, abdominal pain, growth failure, and dysphagia. Dysphagia is a more common presentation in adults and older children. Serious complications of EE consisting of esophageal food impactions necessitating urgent endoscopic removal of the food and esophageal strictures requiring endoscopic balloon dilatations are also seen. The potential severity of these symptoms points to the importance of proper recognition and management of the disease, especially given that EE has become more prevalent over the past decade. In this article, available evidence on the epidemiology and etiology of EE is discussed.     

Counselling patients who have sexual difficulties

Sexuality can be severely affected by ill health and medical treatments. Patients need to discuss sexual issues and counselling may be a nursing role. Many barriers prevent nurses from carrying out this aspect of care in practice. Nurses need to increase their knowledge and skills through education, training and research. Patient needs can be met by providing useful information and counselling.     

Communicating with patients who have dementia

It was not until the 1980s that significant research was carried out on brain disorders. Lack of understanding of dementia has perhaps been the reason for the over-emphasis on physical care, and a failure to see these patients as people with feelings, beliefs and values. Three therapeutic techniques to help practitioners increase and improve communication with people who have dementia are described. It may be that communication is the key to understanding and resolving behaviour disturbances.     

Care of patients who have died

This article outlines the steps involved in preparing the patient after death--known as last offices. It addresses legal and non-legal issues, religious considerations, hygiene care and aftercare for the family.     

Diagnosis and management of eosinophilic esophagitis in children

Question After a few years of difficulty swallowing solids and feeling like food was getting stuck, a 13-year-old boy in my practice with peanut allergy and asthma was recently diagnosed with eosinophilic esophagitis (EoE). What is EoE and how is it diagnosed and managed?Answer Eosinophilic esophagitis is an immune-mediated disease resulting in inflammation of the esophagus. It is increasing in prevalence and incidence in countries like Canada, and frequently occurs in children with other allergic conditions. Unexplained feeding difficulties, vomiting, and solid-food dysphagia, especially in boys with atopy, supports the possibility of having EoE. A formal diagnosis is obtained by reviewing esophageal biopsies obtained through upper endoscopy performed while the patient is taking a proton pump inhibitor. Once EoE has been established, management should involve working collaboratively with gastroenterology and allergy specialists. Medical or dietary treatments are acceptable therapeutic approaches.     

Esophageal strictures in adult eosinophilic esophagitis: dilation is an effective and safe alternative after failure of topical corticosteroids

Strictures are a frequent complication of eosinophilic esophagitis. The efficacy and safety of topical corticosteroids and of dilation of eosinophilic esophagitis-associated strictures have not yet been thoroughly clarified. We present a retrospective analysis of 10 adult patients with eosinophilic esophagitis who had symptomatic esophageal stenosis that was unresponsive to topical corticosteroids, and who were treated using bougienage. Eight patients had one single stricture, one patient had two, and another had three strictures; mean stricture length was 2.1 cm (range 1 - 6 cm). Bougienage led to prompt symptom relief. Apart from transient postprocedural odynophagia, no severe complications occurred. During the follow-up (mean 6 months; range 2 - 11 months), all patients enjoyed sustained treatment response.     

Dyslipidemias in patients who have chronic kidney disease

Patients with CKD are at high risk for developing CVD. In fact, most CKD patients have a 10-year risk of coronary heart disease events greater than or equal to 20%, placing them in the highest risk category according to the National Cholesterol Education Program Adult Treatment Panel III guidelines. For this reason, the National Kidney Foundation K/DOQI guidelines for managing dyslipidemia suggest that CKD patients with LDL greater than or equal to 100 mg/dL (2.59 mmol/L) should be treated with diet and a statin. The K/DOQI guidelines also make it clear that the evidence supporting treatment in CKD populations is lacking however, and that additional placebo-controlled trials are needed. In the mean time, the high incidence of CVD makes intensive monitoring and treatment of dyslipidemias in patients with CKD a reasonable clinical approach.